Precision in Practice: Mastering Biomarker-Driven Management of Metastatic Colorectal Cancer

Video Transcription

Video Summary

This webinar, presented by the American Society for Gastrointestinal Endoscopy and sponsored by Pfizer, focuses on the precision management of metastatic colorectal cancer (CRC) through biomarker-driven care. Gastroenterologist Dr. Juul Sammeter emphasizes the crucial role gastroenterologists play in obtaining biopsies during colonoscopy and initiating timely biomarker testing (e.g., KRAS, NRAS, BRAF, MSI) to guide personalized treatment and improve outcomes. Pathologist Dr. Safiya Salaria highlights the importance of adequate tumor samples for molecular testing, describing methods like immunohistochemistry and next-generation sequencing, and the need for close collaboration between gastroenterologists, pathologists, and oncologists. Oncologist Dr. Christina Wu details actionable genetic mutations and their targeted therapies, stressing comprehensive genomic profiling early in care to optimize treatment decisions. Nurse navigator Bree Robinson outlines her role in educating and coordinating care, ensuring timely workup and testing, and supporting patients throughout their journey. The panel underscores multidisciplinary collaboration to avoid delays and enhance patient advocacy. Genetic testing for inherited cancer risk (germline) and somatic tumor profiling are both vital, with cost and insurance considerations discussed. Overall, integrating biomarker testing early and maintaining coordinated communication among gastroenterology, pathology, oncology, and nursing teams is essential to advancing personalized treatment and improving survival in metastatic CRC patients.

Keywords

metastatic colorectal cancer

biomarker-driven care

gastroenterology

biopsy

molecular testing

genomic profiling

multidisciplinary collaboration

personalized treatment

patient advocacy